{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:51Z","timestamp":1790913711835,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00277-025-06350-w","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T02:29:18Z","timestamp":1744684158000},"page":"2483-2493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India"],"prefix":"10.1007","volume":"104","author":[{"given":"Pritish Chandra","family":"Patra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Rainchwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy J.","family":"Palatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakul","family":"Tikare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tribikram","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul Sharad","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"6350_CR1","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J F, ... & Hochhaus A. (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms.\u00a0Leukemia,\u00a036(7), 1703\u20131719","DOI":"10.1038\/s41375-022-01613-1"},{"key":"6350_CR2","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"6350_CR3","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851\u20132857","journal-title":"J Clin Oncol"},{"key":"6350_CR4","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1097\/HS9.0000000000000468","volume":"4","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R (2020) Chronic myeloid leukemia in 2020. Hemasphere 4:e468","journal-title":"Hemasphere"},{"issue":"04","key":"6350_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(04):966\u2013984","journal-title":"Leukemia"},{"issue":"06","key":"6350_CR6","first-page":"810","volume":"47","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Kukreja M, Goldman JM et al (2012) Prognostic factors for outcomes in allogeneic transplantation forCML in the imatinib era: a CIBMTR analysis. BoneMarrowTransplant 47(06):810\u2013816","journal-title":"BoneMarrowTransplant"},{"issue":"10","key":"6350_CR7","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2019.06.028","volume":"25","author":"A Radujkovic","year":"2019","unstructured":"Radujkovic A, Dietrich S, Blok H-J et al (2019) Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party. Biol Blood Marrow Transplant 25(10):2008\u20132016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"09","key":"6350_CR8","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/bmt.2014.146","volume":"49","author":"H Jiang","year":"2014","unstructured":"Jiang H, Xu LP, Liu DH et al (2014) Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 49(09):1146\u20131154","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"6350_CR9","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628\u20131633","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"6350_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E et al (2021) Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 27(8):642\u2013649","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"6350_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.18620\/ctt-1866-8836-2020-9-4-11-19","volume":"9","author":"H R\u00fcdiger","year":"2020","unstructured":"R\u00fcdiger H (2020) The new ELN Recommendations for treating CML. Early transplantation in patients with high-risk ACA. Cellul Therap Transplant 9(4):11\u201319","journal-title":"Cellul Therap Transplant"},{"issue":"1","key":"6350_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S et al (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22(1):4\u201310","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"6350_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M et al (2015) National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 21(3):389-401.e1","journal-title":"Biol Blood Marrow Transplant."},{"issue":"01","key":"6350_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/0019-509X.134598","volume":"51","author":"NK Thota","year":"2014","unstructured":"Thota NK, Gundeti S, Linga VG, Coca P, Tara RP, Raghunadharao R (2014) Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis. Indian J Cancer 51(01):5\u20139","journal-title":"Indian J Cancer"},{"key":"6350_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R (2012) How I treat CML blast crisis. Blood 120:737\u2013747","journal-title":"Blood"},{"key":"6350_CR16","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J et al (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513\u2013521","journal-title":"Haematologica"},{"key":"6350_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM et al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352:1087\u20131092","journal-title":"Lancet"},{"key":"6350_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","volume":"22","author":"A Gratwohl","year":"2009","unstructured":"Gratwohl A, Heim D (2009) Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 22:431\u2013443","journal-title":"Best Pract Res Clin Haematol"},{"key":"6350_CR19","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.2010.30.4121","volume":"29","author":"A Gratwohl","year":"2011","unstructured":"Gratwohl A, Brand R, Niederwieser D et al (2011) Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29:1980\u20131986","journal-title":"J Clin Oncol"},{"key":"6350_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/leu.2015.281","volume":"30","author":"A Gratwohl","year":"2016","unstructured":"Gratwohl A, Pfirrmann M, Zander A et al (2016) Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 30:562\u2013569","journal-title":"Leukemia"},{"key":"6350_CR21","unstructured":"Genomic rearrangements associated with the t (9; 22) in CML. Library and Archives Canada= Biblioth\u00e8que et Archives Canada, Ottawa.]"},{"key":"6350_CR22","doi-asserted-by":"crossref","unstructured":"Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, ... & Kr\u00f6ger N (2013) Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.\u00a0Annals Hematol 92, 487\u2013496.","DOI":"10.1007\/s00277-012-1650-8"},{"key":"6350_CR23","doi-asserted-by":"crossref","unstructured":"Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, ... Chalandon Y (2019) Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party.\u00a0Biol Blood Marrow Transplant 25(10), 2008\u20132016.","DOI":"10.1016\/j.bbmt.2019.06.028"},{"key":"6350_CR24","doi-asserted-by":"crossref","unstructured":"Defilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, ... & Saber W (2020). Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a center for international blood and marrow transplant research study.\u00a0Biol Blood Marrow Transpl 26(3), 472\u2013479.","DOI":"10.1016\/j.bbmt.2019.10.017"},{"issue":"1","key":"6350_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/JGO.2015.002667","volume":"3","author":"P Ganesan","year":"2017","unstructured":"Ganesan P, Kumar L (2017) Chronic myeloid leukemia in India. J Glob Oncol 3(1):64\u201371","journal-title":"J Glob Oncol"},{"issue":"15","key":"6350_CR26","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A (2017) Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer 123(15):2875\u20132880","journal-title":"Cancer"},{"issue":"12","key":"6350_CR27","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.bbmt.2019.07.037","volume":"25","author":"A Candoni","year":"2019","unstructured":"Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, Parma M (2019) Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors: a registry-based study of the Italian Blood and Marrow Transplantation Society (GITMO). Biol Blood Marrow Transplant 25(12):2388\u20132397","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"6350_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.clml.2020.07.005","volume":"20","author":"S Nanno","year":"2020","unstructured":"Nanno S, Matsumoto K, Nakamae M, Okamura H, Nishimoto M, Hirose A, Koh H, Nakashima Y, Nakane T, Morita K, Hino M (2020) Effect of prophylactic post-transplant ponatinib administration on outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphom Myeloma Leukemia 20(12):813\u2013819","journal-title":"Clin Lymphom Myeloma Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06350-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06350-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06350-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:13:48Z","timestamp":1746414828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06350-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6350"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06350-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Institutional Review Board of our Centre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval statement"}},{"value":"Patient Permission to publish the data has been taken from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the author(s) used ChatGPT in order to improve Grammatical errors of the manuscript. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process:"}}]}}